India SC questions 30% cancer drug margin cap, putting UAE pharmacy markups in focus

India’s Supreme Court on 12 October 2026 asked why a proposed 30% trade-margin cap for selected cancer medicines should stop at oncology drugs, a question that UAE clinics, insurers and pharmacy operators should read as a margin-risk warning rather than an India-only dispute.

The immediate exposure for UAE operators is reputational and contractual. Dubai providers regulated by the Dubai Health Authority (DHA), Abu Dhabi and Al Ain providers regulated by the Department of Health Abu Dhabi (DOH), and northern emirates providers licensed through the Ministry of Health and Prevention (MOHAP) operate in a market where patients can compare pharmacy access, insurance acceptance and cash prices within minutes.

What the Supreme Court asked

A bench of Justices Vikram Nath and Sandeep Mehta questioned the Centre’s decision to limit the proposed margin cap to specified cancer drugs, according to an ANI report published by Devdiscourse. Solicitor General Tushar Mehta told the court that India would notify a list of cancer drugs covered by the cap and update it over time.

“This relates to only cancer drugs. What about the overall?” — Justices Vikram Nath and Sandeep Mehta, Supreme Court of India

The court cited several pricing gaps. It referred to a saline drip line with an MRP of Rs 270 against a sale price of Rs 11, and an Indian-made cardiac stent with a price to retailer of Rs 5,000 and MRP of Rs 25,000. In an earlier September hearing, the same bench questioned a cancer medicine with a Rs 2,700 price to retailer and Rs 27,000 MRP, according to India Today.

Why this matters in Dubai first

Dubai’s pharmacy market is dense and searchable. The UAE Open Healthcare Directory lists 1,680 licensed pharmacies in Dubai, with filters for insurance, neighbourhood and operating hours. That changes patient behaviour. A cash-paying patient who sees a high medicine bill after a consultation can compare nearby licensed providers before leaving the area.

For CFOs, the first task is to separate medicine revenue from clinical revenue in management accounts. For COOs, the task is operational: review whether discharge teams, oncology units, day surgery centres and infusion suites allow patients to use external licensed pharmacies when clinically safe and permitted by payer rules. For insurers, including Daman, Thiqa and Sukoon where policy networks apply, the question is whether pharmacy benefit rules reward lower-cost dispensing or push patients into a narrow provider channel.

• Cash-price check: routine generic medicine prices in Dubai are commonly shown in the AED 10-50 range on provider directory guidance, but operators should verify each registered product through official channels.
• Product check: the Emirates Drug Establishment (EDE) Drug Directory showed 17,107 registered product results after its 10 September 2026 dataset refresh.
• Price-list check: EDE provides a service to request a medical products price list for registered UAE medical products.
• Facility check: DHA’s Sheryan system includes a public medical registry for licensed Dubai facilities and professionals.

The UAE comparison

The UAE already has a more centralised medicine-registration layer than India’s fragmented state and federal debate. EDE maintains the national product directory and price-list service. DHA, DOH Abu Dhabi and MOHAP then sit closer to the provider and facility level. That split matters because the same invoice can involve a federally registered product, an emirate-licensed pharmacy and an insurer-specific reimbursement rule.

Clinic owners should watch India for one signal: courts and regulators are paying closer attention to the gap between acquisition cost, listed price and patient-paid price. In the UAE, that gap may appear in oncology medicines, injectables, consumables, implants, diabetic supplies and branded chronic-disease drugs. The risk is highest where the patient has limited time to shop, such as cancer care, emergency discharge, day-case surgery and maternity episodes.

The practical step is a 30-day pharmacy margin audit. Pull the top 50 dispensed medicines and devices by revenue, compare billed price with insurer reimbursement and patient co-pay, then record whether a licensed external pharmacy option was available. Where a number cannot be verified internally, use the EDE Drug Directory and EDE price-list request service before quoting it to patients.

For patients and operators checking licensed pharmacy options, start with the UAE Open Healthcare Directory, which lists 12,394+ licensed healthcare providers across all seven emirates and includes pharmacy providers by city, insurance and operating hours.